Our human pluripotent stem cell (hPSC) technology platform, Human Clinical Trials in a Test Tube™, is based upon a combination of proprietary and exclusively licensed hPSC technologies, including technologies developed over the last 20 years by our co-founders, renowned Canadian stem cell scientist, Dr. Gordon Keller, and Dr. Ralph Snodgrass, our President and Chief Scientific Officer.

The proprietary and licensed hPSC technologies underlying our Human Clinical Trials in a Test Tube™ platform enable controlled differentiation of hPSCs into mature human cells specific to our current and potential predictive toxicology, drug metabolism, drug rescue and regenerative medicine programs and commercial opportunities.


Controlled differentiation of hPSCs into mature, functional human cells could allow the identification of new drug candidates that exhibit human toxicity or metabolism issues early in the drug development process, resulting in more efficient focusing of resources on those drug candidates with the highest probability of success. We believe this has the potential to substantially reduce drug development costs and produce effective and safer drugs.

The combination of our proprietary and licensed hPSC technologies enables the development of 3D human cell-based bioassay systems that consist of large numbers of normal, non-transformed, human cells that function as “micro-organs”.

The 3D micro-organ cultures induce the cells to grow, mature, and develop 3D cell networks and tissue structures. Compared to traditional flat 2D cell-based assays, these 3D cell networks and structures are believed to more accurately reflect the structures and biology inside the human body and are expected to yield responses to new small molecule drug candidates that are more clinically predictive of human drug responses.

We believe that our Human Clinical Trials in a Test Tube™ platform will allow the assessment of the toxicity and metabolism (drug-drug interaction) profile of new small molecule drug candidates for a wide range of diseases and conditions with greater speed and precision than nonclinical in vitro techniques and technologies currently used by biotechnology and pharmaceutical companies in the drug development process.